ATE271553T1 - Neue cyclische und acyclische amide zur erhöhung der neurotransmitter ausschüttung - Google Patents
Neue cyclische und acyclische amide zur erhöhung der neurotransmitter ausschüttungInfo
- Publication number
- ATE271553T1 ATE271553T1 AT95910708T AT95910708T ATE271553T1 AT E271553 T1 ATE271553 T1 AT E271553T1 AT 95910708 T AT95910708 T AT 95910708T AT 95910708 T AT95910708 T AT 95910708T AT E271553 T1 ATE271553 T1 AT E271553T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- neurotransmitter release
- new cyclic
- sec
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
- C07D213/20—Quaternary compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/06—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23674394A | 1994-04-29 | 1994-04-29 | |
PCT/IB1995/000189 WO1995029909A1 (en) | 1994-04-29 | 1995-03-20 | Novel acyclic and cyclic amides as neurotransmitter release enhancers |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE271553T1 true ATE271553T1 (de) | 2004-08-15 |
Family
ID=22890767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95910708T ATE271553T1 (de) | 1994-04-29 | 1995-03-20 | Neue cyclische und acyclische amide zur erhöhung der neurotransmitter ausschüttung |
Country Status (14)
Country | Link |
---|---|
US (1) | US5854232A (de) |
EP (1) | EP0757685B1 (de) |
JP (4) | JP3004728B2 (de) |
AT (1) | ATE271553T1 (de) |
AU (1) | AU1884595A (de) |
CA (1) | CA2188427C (de) |
DE (1) | DE69533284T2 (de) |
DK (1) | DK0757685T3 (de) |
ES (1) | ES2223049T3 (de) |
FI (1) | FI964340A0 (de) |
IL (1) | IL113436A0 (de) |
MX (1) | MX9605218A (de) |
PT (1) | PT757685E (de) |
WO (1) | WO1995029909A1 (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09183725A (ja) * | 1995-09-01 | 1997-07-15 | Pfizer Inc | ガン治療用治療剤 |
BR9709974A (pt) * | 1996-06-27 | 1999-08-10 | Pfizer | Derivados de 2-(2-oxo-etidileno)-imidazolidin-4-ona e seu uso como inibidores da transferase da proteina de farnesila |
PT870757E (pt) * | 1997-04-10 | 2002-09-30 | Pfizer | Derivados de adamantano substituidos por fluoro |
GB9716879D0 (en) * | 1997-08-08 | 1997-10-15 | Shire Int Licensing Bv | Treatment of attention deficit disorders |
US6589450B1 (en) | 1997-11-25 | 2003-07-08 | Ljubov Robertovna Bratkova | Light-converting material and composition for producing the same |
US6262081B1 (en) * | 1998-07-10 | 2001-07-17 | Dupont Pharmaceuticals Company | Composition for and method of treating neurological disorders |
ES2306665T3 (es) * | 1999-07-21 | 2008-11-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Pequeñas moleculas utiles en el tratamiento de la enfermedad inflamatoria. |
US20050074487A1 (en) * | 1999-12-16 | 2005-04-07 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
AU6067401A (en) * | 2000-05-31 | 2001-12-11 | Santen Pharmaceutical Co Ltd | Tnf-alpha production inhibitors |
US7585523B2 (en) * | 2002-08-27 | 2009-09-08 | Targeted Medical Pharma | Composition and method to augment and sustain neurotransmitter production |
EP1603595B1 (de) * | 2003-02-27 | 2010-11-10 | Eisai R&D Management Co., Ltd. | Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit |
ATE420881T1 (de) | 2003-09-17 | 2009-01-15 | Janssen Pharmaceutica Nv | Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors |
AU2006278759B2 (en) * | 2005-08-04 | 2012-08-16 | Janssen Pharmaceutica N.V. | Pyrimidine compounds as serotonin receptor modulators |
US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
US8168667B2 (en) | 2006-05-31 | 2012-05-01 | Galapagos Nv | Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such |
KR20090057388A (ko) * | 2006-09-27 | 2009-06-05 | 닛산 가가쿠 고교 가부시키 가이샤 | 숙신이미드 화합물의 제조 방법 |
TW201010975A (en) | 2008-08-29 | 2010-03-16 | Kowa Co | 1-adamantylazetidin-2-one derivatives and drugs containing same |
GB2463514C (en) | 2008-09-11 | 2018-09-26 | Galapagos Nv | Imidazolidine compounds and uses therefor |
EP3610890A1 (de) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Verfahren und zusammensetzungen zur behandlung von schizophrenie |
CN108610292B (zh) * | 2018-06-12 | 2020-11-10 | 清华大学 | 一类3,5-二取代乙内酰脲类化合物及其制备方法与应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4216318A (en) * | 1975-12-29 | 1980-08-05 | Smith Kline & French Laboratories Limited | Heterocyclic alkyl 4-pyrimidones |
US4760083A (en) * | 1986-04-10 | 1988-07-26 | E. I. Dupont De Nemours & Company | 3,3-disubstituted indolines |
US5173489A (en) * | 1986-04-10 | 1992-12-22 | The Dupont Merck Pharmaceutical Co. | α,α-disubstituted aromatics and heteroaromatics as cognition enhancers |
DE69034103T2 (de) * | 1989-06-14 | 2004-07-15 | Smithkline Beecham Corp. | Imidazoalkensäure |
US5006537A (en) * | 1989-08-02 | 1991-04-09 | Hoechst-Roussel Pharmaceuticals, Inc. | 1,3-dihydro-1-(pyridinylamino)-2H-indol-2-ones |
DE69218795T2 (de) * | 1992-01-16 | 1997-07-10 | Du Pont Merck Pharma | Verbindungen,die neurotransmitter freisetzen,um die lernfähigkeit zu erhöhen |
US5278162A (en) * | 1992-09-18 | 1994-01-11 | The Du Pont Merck Pharmaceutical Company | 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man |
TW444018B (en) * | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
US6765008B1 (en) * | 1992-12-17 | 2004-07-20 | Pfizer Inc | Pyrrolopyrimidines as CRF antagonists |
WO1995010506A1 (en) * | 1993-10-12 | 1995-04-20 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
TW574214B (en) * | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
-
1995
- 1995-03-20 EP EP95910708A patent/EP0757685B1/de not_active Expired - Lifetime
- 1995-03-20 US US08/737,376 patent/US5854232A/en not_active Expired - Fee Related
- 1995-03-20 PT PT95910708T patent/PT757685E/pt unknown
- 1995-03-20 AU AU18845/95A patent/AU1884595A/en not_active Abandoned
- 1995-03-20 WO PCT/IB1995/000189 patent/WO1995029909A1/en active IP Right Grant
- 1995-03-20 CA CA002188427A patent/CA2188427C/en not_active Expired - Fee Related
- 1995-03-20 ES ES95910708T patent/ES2223049T3/es not_active Expired - Lifetime
- 1995-03-20 MX MX9605218A patent/MX9605218A/es not_active IP Right Cessation
- 1995-03-20 DK DK95910708T patent/DK0757685T3/da active
- 1995-03-20 JP JP7528089A patent/JP3004728B2/ja not_active Expired - Fee Related
- 1995-03-20 AT AT95910708T patent/ATE271553T1/de not_active IP Right Cessation
- 1995-03-20 DE DE69533284T patent/DE69533284T2/de not_active Expired - Fee Related
- 1995-04-20 IL IL11343695A patent/IL113436A0/xx unknown
-
1996
- 1996-10-28 FI FI964340A patent/FI964340A0/fi not_active IP Right Cessation
-
1998
- 1998-10-13 JP JP29066498A patent/JP3432753B2/ja not_active Expired - Fee Related
- 1998-10-13 JP JP29068298A patent/JP3158103B2/ja not_active Expired - Fee Related
- 1998-10-13 JP JP29063698A patent/JP3281320B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE69533284T2 (de) | 2005-07-21 |
JPH09506371A (ja) | 1997-06-24 |
CA2188427A1 (en) | 1995-11-09 |
JP3432753B2 (ja) | 2003-08-04 |
DE69533284D1 (de) | 2004-08-26 |
JPH11217371A (ja) | 1999-08-10 |
AU1884595A (en) | 1995-11-29 |
JPH11193273A (ja) | 1999-07-21 |
ES2223049T3 (es) | 2005-02-16 |
PT757685E (pt) | 2004-10-29 |
JP3158103B2 (ja) | 2001-04-23 |
JP3004728B2 (ja) | 2000-01-31 |
MX9605218A (es) | 1997-10-31 |
DK0757685T3 (da) | 2004-10-25 |
WO1995029909A1 (en) | 1995-11-09 |
IL113436A0 (en) | 1995-07-31 |
JP3281320B2 (ja) | 2002-05-13 |
FI964340A (fi) | 1996-10-28 |
JPH11209374A (ja) | 1999-08-03 |
EP0757685A1 (de) | 1997-02-12 |
US5854232A (en) | 1998-12-29 |
CA2188427C (en) | 2000-06-27 |
EP0757685B1 (de) | 2004-07-21 |
FI964340A0 (fi) | 1996-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE271553T1 (de) | Neue cyclische und acyclische amide zur erhöhung der neurotransmitter ausschüttung | |
MXPA04000278A (es) | Uso de antagonistas del receptor nk-1 con estructura piridinica para tratamiento de lesiones cerebrales, espinales o neuronales. | |
GB9426103D0 (en) | Therapeutic agents | |
HU9401337D0 (en) | Acyclic ethylenediamine derivatives as substance p receptor antagonists | |
MX9307062A (es) | Derivado de quinuclidina para el tratamiento de los trastornos inflamatorios y del sistema nervioso central. | |
MXPA05009359A (es) | Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6. | |
ATE451368T1 (de) | Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems | |
LV11738A (lv) | Tropan-2-aldoksima atvasinajumi ka neiromediatoru resorbcijas inhibitori | |
TW200509933A (en) | Therapeutic agents | |
FI19992038A (fi) | Menetelmä atsepinonien valmistamiseksi | |
BRPI0410026A (pt) | derivados de 3-amino-croman quinolina | |
DK0815109T3 (da) | Fremgangsmåde til fremstilling af estere af anhydroecgonin | |
ES2119454T3 (es) | Derivados de pirrolidina para el tratamiento de los desordenes relacionados con la csk y la gastrina. | |
HK1098668A1 (en) | Use of 1,3-diaza-dibenzo Äe.hÜ azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0757685 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |